



## **Intergalactic Therapeutics to Present Updated Data From Its Non-Viral Gene Therapy Platform at the 2023 Retinal Cell and Gene Therapy Innovation Summit**

***Lead program, IG-002 targeting ABCA4 retinopathies, demonstrates durable 12-month expression of human ABCA4 protein using a single subretinal dose of DNA payload***

**CAMBRIDGE, Mass., April 20, 2023** – [Intergalactic Therapeutics](#), a company focused on transforming medicine through non-viral gene therapy, announced today that **Gayathri Ramaswamy, Ph.D.**, Vice President, Drug Discovery and Disease Biology, will present at the [Annual Retinal Cell and Gene Therapy Innovation Summit](#) on April 21, 2023 at the Marriott New Orleans Warehouse Arts District in New Orleans, Louisiana.

“We are excited to share encouraging preclinical data from our lead program, IG-002 targeting *ABCA4*-associated retinopathies. Data to be presented demonstrate for the first time that a non-viral gene therapy is able to achieve long-term, persistent protein expression with a single administration,” said **Theresa G.H. Heah, M.D., M.B.A.**, Chief Executive Officer of Intergalactic Therapeutics. “We believe that our C<sup>3</sup>DNA platform holds the potential to make non-viral gene therapies a reality, and with these data in hand, we are working to rapidly advance IG-002 through IND-enabling studies and into the clinic.”

### **Presentation details are as follows:**

**Presentation Title:** A novel, non-viral approach to delivering full length *ABCA4* to photoreceptors

**Date and Time:** Friday, April 21, 2023 at 10:45 a.m. to 11:00 a.m. CT

**Presenter:** Gayathri Ramaswamy, Ph.D., Vice President, Drug Discovery and Disease Biology at Intergalactic Therapeutics

Dr. Ramaswamy will share preclinical results from Intergalactic’s lead program IG-002 addressing all forms of *ABCA4*-related retinopathies. The data demonstrate for the first time that a single subretinal administration of a DNA payload encoding the human *ABCA4* gene resulted in durable (12-month) expression of human *ABCA4* protein in adult porcine retinas. The expression levels achieved suggest potential therapeutic benefit in individuals living with *ABCA4*-related retinopathies.

In the study, full-length *ABCA4* DNA was packaged into Intergalactic’s proprietary C<sup>3</sup>DNA (covalently closed and circular DNA) cargo platform, and was delivered using COMET, Intergalactic’s proprietary electro-transfer based system for targeted delivery of C<sup>3</sup>DNA.

### **About Intergalactic Therapeutics**

Intergalactic Therapeutics, an [Apple Tree Partners \(ATP\)](#) company, is transforming medicine through non-viral gene therapy. Its proprietary integrated platform comprises three core pillars: versatile C<sup>3</sup>DNA technology (covalently closed and circular DNA); groundbreaking precise and tunable approaches to local therapeutic delivery using the COMET electro-transfer system; and

a rapid, scalable, and cost-effective manufacturing process to make gene therapy safer and more accessible. With a diversified portfolio of potential new treatments for eye diseases and beyond, Intergalactic is dedicated to helping patients around the world by bringing non-viral gene therapies into reality. For more information, visit [www.intergalactictx.com](http://www.intergalactictx.com).

**Company contact:** [info@intergalactictx.com](mailto:info@intergalactictx.com)